Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02478281
Recruitment Status : Completed
First Posted : June 23, 2015
Last Update Posted : January 25, 2018
Sponsor:
Information provided by (Responsible Party):
American Regent, Inc.

Brief Summary:
A Phase 1 trial to assess the single-dose safety, tolerability, and pharmacokinetic (PK) of Methylene Blue Injection, USP 1 mg/kg in healthy adult voluneetrs.

Condition or disease Intervention/treatment Phase
Methemoglobinemia Congenital Methemoglobinemia Drug: Methylene Blue Phase 1

Detailed Description:
This is an open-label, single-center, one-arm, safety, tolerability, and PK study in healthy male and female volunteers of Methylene Blue Injection, USP. Following an overnight fast, twelve healthy adult male and female volunteers will receive a single dose of study drug at a dose of 1 mg/kg solution per kg given intravenously over a period of 5 minutes followed by serial venous blood sampling at 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours postdose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A One-Period, Single-Dose, Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Injection USP Following a 1 mg/kg Intravenous Dose in Healthy Adult Volunteers
Study Start Date : October 2012
Actual Primary Completion Date : October 2012
Actual Study Completion Date : March 2013


Arm Intervention/treatment
Experimental: Methylene Blue Injection, USP
Single dose of Methylene Blue Injection, USP at a dose of 1 mg/kg solution per kg given intravenously over a period of approximately 5 minutes.
Drug: Methylene Blue



Primary Outcome Measures :
  1. Assess the AUC0-t (ng*hr/mL) of Methylene Blue [ Time Frame: 72 hours postdose ]
  2. Assess the AUC0- infinity (ng*hr/mL) of Methylene Blue [ Time Frame: 72 hours postdose ]
  3. Assess the AUC%extrap (%) of Methylene Blue [ Time Frame: 72 hours postdose ]
  4. Assess the AUCR (%) of Methylene Blue [ Time Frame: 72 hours postdose ]
  5. Assess the CL (L/hr) of Methylene Blue [ Time Frame: 72 hours postdose ]
  6. Assess the Cmax (ng/mL) of Methylene Blue [ Time Frame: 72 hours postdose ]
  7. Assess the tmax (hr) of Methylene Blue [ Time Frame: 72 hours postdose ]
  8. Assess the t½ (hr) of Methylene Blue [ Time Frame: 72 hours postdose ]
  9. Asses the λz (1/hr) of Methylene Blue [ Time Frame: 72 hours postdose ]
  10. Assess the Vz (L) of Methylene Blue [ Time Frame: 72 hours postdose ]
  11. Assess the MRT (hr) of Methylene Blue [ Time Frame: 72 hours postdose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult male or female volunteers, 18-60 years of age, inclusive.
  • Weigh at least 52 kg for males and 45 kg for females and within the normal range according to accepted normal values of the Body Mass Index (BMI) chart 18.5-29.9 kg/m² inclusive.
  • Medically healthy with no clinically significant laboratory profiles, vital signs, or ECG's; as deemed by the PI.
  • For females of childbearing potential: either be sexually inactive (abstinent) for 14 days prior to the first dose and throughout the study or be using acceptable birth control methods. Female subjects who claim to be sexually inactive, but become sexually active during the course of the study must agree to use a barrier method (e.g. condom, diaphragm)with spermicide from the time of the start of sexual activity through at least 30 days following dosing. In addition, female subjects of childbearing potential will be advised to remain sexually inactive or to keep the same birth control method for at least 30 days following dosing.
  • Females of non-childbearing potential must have undergone one of the following sterilization procedures at least 6 months prior to Day 1:

    • Hysteroscopic tubal ligation (with a copy of the confirmation test) and be using a barrier method (condom or diaphragm) and spermicide throughout the study;
    • Bilateral tubal ligation and be using a barrier method (condom or diaphragm) and spermicide throughout the study;
    • Hysterectomy;
    • Bilateral oophorectomy or be postmenopausal with amenorrhea for at least 1 year prior to Day 1 and follicle stimulating hormone (FSH) serum levels ≥ 40 mIU/mL. Females on hormone replacement therapy may be deemed eligible for participation in the study even if their FSH levels < 40 mIU/mL, if they are able to provide documentation of FSH levels 40 mIU/mL before initiation of hormone replacement therapy.
  • Males must use condom with spermicide when engaged in sexual activity and must agree to refrain from sperm donation from check-in through 90 days postdose.
  • Willing to answer inclusion and exclusion criteria questionnaire at check-in.
  • Give voluntary written informed consent to participate in the study.
  • Be able to comply with the protocol and the assessments therein.

Exclusion Criteria:

  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease in the opinion of the PI.
  • History or presence of alcoholism within the past 2 years.
  • History or presence of drug abuse within the past 2 years.
  • History or presence of hypersensitivity or idiosyncratic reaction to Methylene Blue.
  • History or presence of G6PD dehydrogenase deficiency, retinopathy, blood disorder, myasthenia gravis, psoriasis, epilepsy, clinically significant allergies (except for mild forms of hay fever), or any other clinically significant medical condition, which in the opinion of the PI, might interfere with study participation.
  • History or laboratory evidence of renal insufficiency.
  • Any screening laboratory test with clinically significant abnormalities in the opinion of the PI (including cell blood count, creatinine, or liver function tests).
  • Have used any drug that acts as a seotonin reuptake inhibitor (SRIs) e.g. selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), norepinephrine-dopamine reuptake inhibitors (NDRIs), triptans, or ergot alkaloids within 30 days (or 5 half-lives of the compound, whichever is longer) prior to study drug dosing.
  • Female subjects who are pregnant or lactating, or female subjects who are likely to become pregnant during the study.
  • Had positive results for the urine drug/alcohol screen at screening or check-in.
  • Had positive results at screening for HIV, HBsAg, or HCV.
  • Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
  • Heart rate is lower than 40 bpm or higher than 99 bpm at screening.
  • QTc interval is >430 msec (males) or >450 msec (females) or deemed clinically abnormal by the PI or use of any drug or agent suspected of causing QT prolongation or torsade de pointes within 14 days (or 5 half- lives of the compound, whichever is longer) prior to study drug dosing.
  • Have been on a special diet (for whatever reason) within the 28 days prior to study drug dosing, and throughout the study.
  • Have made a donation of blood or had significant blood loss within 56 days prior to study drug dosing.
  • Have made a plasma donation within 7 days prior to study drug dosing.
  • Have received Methylene Blue within 72 hours prior to study drug dosing.
  • Have participated in another clinical trial within 30 days (or 5 half-lives of the compound, whichever is longer) prior to study drug dosing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02478281


Sponsors and Collaborators
American Regent, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Fareeda Hosein, MD Celerion
Layout table for additonal information
Responsible Party: American Regent, Inc.
ClinicalTrials.gov Identifier: NCT02478281    
Other Study ID Numbers: 1MBL12002
First Posted: June 23, 2015    Key Record Dates
Last Update Posted: January 25, 2018
Last Verified: January 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Methemoglobinemia
Hematologic Diseases
Methylene Blue
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action